Memorial Sloan Kettering researchers ran a pilot study testing whether a chatbot-style AI system could plan liver biopsy needle paths in a controlled setting. The work evaluates the feasibility of using GPT-4.1 for needle trajectory planning, with the team reporting only a cautious, artificial-environment assessment rather than a clinical validation. The core concept is to reduce procedural variability by generating candidate needle paths based on patient imaging and constraints—an approach that could later integrate with real-time navigation systems. However, the results are framed as early-stage feasibility, not readiness for routine bedside use. For the biotech and medtech ecosystem, the pilot is part of a broader shift toward AI-assisted workflows in interventional oncology—where image understanding and tool-path generation must be both accurate and reliable under strict safety requirements.